News & Press releases | Merz Therapeutics

19.11.2024

Merz Therapeutics and S3 Connected Health Pioneer...

Merz Therapeutics launches iFlexo, a personalized digital solution aimed at enhancing rehabilitation for people with post-stroke spasticity as part of its ongoing commitment to supporting stroke...

News Release

24.10.2024

Merz Therapeutics and World Stroke Organization...

Frankfurt, Germany, October 24, 2024 – Today, at the annual World Stroke Congress in Abu Dhabi, the President of the World Stroke Organization (WSO), Dr. Sheila Martins, officially announced a...

News Release

30.07.2024

Merz Therapeutics Appoints Leonard Paolillo as...

Merz Therapeutics announces today the appointment of Leonard Paolillo as President, Merz Therapeutics North America, effective immediately. In this role, Leonard will join the Global Therapeutics...

News Release

10.07.2024

Merz Therapeutics Closes $185M Asset Purchase...

Acquisition of INBRIJA (levodopa inhalation powder) and (F)AMPYRA (fampridine) expands specialty neurology portfolio. Lays groundwork for Parkinson’s disease franchise and anchor in multiple...

News Release

14.06.2024

XEOMIN® (incobotulinumtoxinA) receives a new...

Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, received approval from Swissmedic, the national authorization and supervisory authority for drugs and medical...

News Release

11.01.2024

Personnel announcement: Michael Pfeil appointed...

Merz Therapeutics, a business of the Merz Group and leader in the field of neurotoxins, announces the promotion of Dr. Michael Pfeil to the role of Head of Therapeutics Operations, effective January...

News Release

15.12.2023

MERZ THERAPEUTICS ACHIEVES GLOBAL RECOGNITION AS...

Ten of the Merz Therapeutics subsidiaries' participating countries received esteemed employer certifications.

News Release

22.11.2023

XEOMIN® (incobotulinumtoxinA) receives three new...

Merz Therapeutics, a business of the Merz Group and leader in the field of neurotoxins, has received approval from the Therapeutic Goods Administration (TGA) in Australia for the use of...

News Release

02.11.2023

Merz Therapeutics announces the appointment of...

Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, is pleased to announce the appointment of Mark Altmeyer as a Non-Executive Director, with effect from 01...

News Release

06.10.2023

Merz Therapeutics Hosts Over 300 International...

Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, kicked off its first “Merz Expert Connect Summit” today. The event focuses on advanced treatment options for...

News Release

28.06.2023

Merz Therapeutics Expands Business with New...

Merz Therapeutics, a company of the Merz Group and a leader in the field of neurotoxins, celebrates the opening of its new affiliate in Stockholm for the Nordic region including Denmark, Sweden, and...

News Release

07.06.2023

XEOMIN® (incobotulinumtoxinA) receives a new...

Merz Therapeutics, received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom

News Release

01.03.2023

New CEO for Merz Therapeutics: Stefan König

Mexico City, London, and now Frankfurt am Main, Germany: Experienced Pharma manager appointed to lead Merz Therapeutics

News Release

07.02.2022

Merz strengthens partnership with start-up...

Merz Therapeutics, a company of the Merz Group and a leader in the field of neurotoxins, is expanding its strategic partnership with Vensica Therapeutics